{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-003506","form_type":"8-K","ticker":"SGMO","cik":"0001001233","company_name":"SANGAMO THERAPEUTICS, INC","filed_at":"2024-02-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.027997+00:00","generated_at":"2026-06-06T07:37:00.116133+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Sangamo: ST-920 gene therapy shows sustained efficacy; defers Phase 3 pending partnership","bullets":["As of Sep 19, 2023 cutoff, 24 patients dosed; all 12 withdrawn from ERT remain off ERT with sustained supraphysiological α-Gal A activity.","In dose escalation phase, all 9 patients had sustained elevated α-Gal A activity for nearly 3 years; 5 ERT patients completed withdrawal.","At highest dose (2.63×10^13 vg/kg), ERT-naïve patients showed supraphysiological α-Gal A up to ~500 days with lyso-Gb3 reduction/stabilization.","Mean annualized eGFR slope -0.915 mL/min/1.73m²/yr; 69% improved total FOS-MSSI; statistically significant SF-36 and GSRS improvements.","Company defers further investment in registrational trial planning until collaboration partnership or financing is secured."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-003506","json":"https://secwatch.observer/filing/0001628280-24-003506.json","markdown":"https://secwatch.observer/filing/0001628280-24-003506.md","text":"https://secwatch.observer/filing/0001628280-24-003506.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1001233/000162828024003506/0001628280-24-003506-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1001233/000162828024003506/sgmo-20240205.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T07:37:00.116133+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}